Chanos details Valiant's pro-forma accounting fraud as business model exploiting SEC rules
Valiant grew by acquiring off-patent drugs, booking purchase price as acquired R&D/goodwill, then adding back amortization as 'non-cash' to report pro-forma EPS while GAAP showed…